Brought to you by 
Leo Pharma gains worldwide license to JW Pharma's JW1601 oral atopic dermatitis candidate
12 Oct 2018
Executive Summary
Leo Pharma AS licensed exclusive worldwide development and commercialization rights (except in Korea) to JW Pharmaceutical Corp.'s preclinical atopic dermatitis candidate JW1601.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Leo Pharma gains worldwide license to JW Pharma's JW1601 oral atopic dermatitis candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice